• Orbis will help to improve the Pharmaceutical Technologies occupation of Adare
• Its platforms generally develop drug particles dosed in injectable, oral and otic formulations

Adare Pharmaceuticals Inc., a clinical-stage pharmaceutical firm as well as a global provider of pharmaceutical technologies, manufacturing and development services, has recently announced that it has made the acquisition of Orbis Biosciences, a pharmaceutical technology firm from Lenexa, KS.

The purchase of Orbis will help to improve the Pharmaceutical Technologies business of Adare that both develops and manufactures products for the animal health, global pharmaceutical over-the-counter (OTC) markets.

Adare Pharmaceuticals CEO, John Fraher said that the customized technologies offered by Orbis will prove to be an excellent complement to the company’s contract development and manufacturing organization (CDMO) business that is mostly focused on the OTC and pharmaceutical medicines of oral dosage forms.

Fraher further stated that Orbis platforms generally develop drug particles that are capable of being dosed in an injectable, otic and oral liquid or dosage forms. This will help the company broaden its offerings for product development and gradually advance the CDMO business growth, helping strengthen the leadership in the controlled-release and taste-making technologies.

Apparently, Orbis offers advanced technologies within a single-step and a scaled manufacturing process. The Precision Particle Fabrication technology has been the only one currently on the market that is capable of producing uniform sizes in a wide range of sizes that is suitable for usage within the otic, oral dosage and injectable forms.

The platform technology is customizable and even flexible to be able to accommodate a wide range of active ingredients that also include peptides, proteins and small molecules. The propriety technology of Orbis mainly involves three platforms like StratμmTM, used for injectable delivery; Unisun, to be used for otic delivery and finally Optimμm, to be used for oral delivery.

Orbis Biosciences’ CEO and President, Maria Flynn said that the deal will help globalize the company’s technology as well as its services. The focus on precise delivery solutions of Orbis has helped the company create expertise in the formulations as well as collaborate with bigger partners.

Source Credit- https://www.adarepharma.com/press-release/orbis-announcement/